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Abstract
Androgen ablation therapy is currently the primary treatment for metastatic prostate cancer. Unfortunately, in nearly all
cases, androgen ablation fails to permanently arrest cancer progression. As androgens like testosterone are withdrawn,
prostate cancer cells lose their androgen sensitivity and begin to proliferate without hormone growth factors. In this study,
we constructed and analyzed a mathematical model of the integration between hormone growth factor signaling,
androgen receptor activation, and the expression of cyclin D and Prostate-Specific Antigen in human LNCaP prostate
adenocarcinoma cells. The objective of the study was to investigate which signaling systems were important in the loss of
androgen dependence. The model was formulated as a set of ordinary differential equations which described 212 species
and 384 interactions, including both the mRNA and protein levels for key species. An ensemble approach was chosen to
constrain model parameters and to estimate the impact of parametric uncertainty on model predictions. Model parameters
were identified using 14 steady-state and dynamic LNCaP data sets taken from literature sources. Alterations in the rate of
Prostatic Acid Phosphatase expression was sufficient to capture varying levels of androgen dependence. Analysis of the
model provided insight into the importance of network components as a function of androgen dependence. The
importance of androgen receptor availability and the MAPK/Akt signaling axes was independent of androgen status.
Interestingly, androgen receptor availability was important even in androgen-independent LNCaP cells. Translation became
progressively more important in androgen-independent LNCaP cells. Further analysis suggested a positive synergy between
the MAPK and Akt signaling axes and the translation of key proliferative markers like cyclin D in androgen-independent
cells. Taken together, the results support the targeting of both the Akt and MAPK pathways. Moreover, the analysis
suggested that direct targeting of the translational machinery, specifically eIF4E, could be efficacious in androgen-
independent prostate cancers.
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Introduction
Prostate cancer is the most common cancer in men and the
second leading cause of cancer-related death in the United States
[1]. It has been known since the 1940s that androgens, such as
testosterone, are required for prostate cancer growth [2].
Accordingly, androgen ablation in combination with radiation or
traditional chemotherapy remains the primary non-surgical
treatment for androgen-dependent prostate cancer. Androgen
ablation initially leads to decreased tumor growth and reduced
secretion of biomarkers such as Prostate Specific Antigen (PSA)
[3–5]. However, in nearly all cases androgen ablation fails to
permanently arrest cancer progression. As testosterone is with-
drawn, malfunctioning prostate cells lose their sensitivity to
androgen and begin to proliferate without hormone growth factor
signals. These testosterone insensitive cells can then lead to
Androgen-Independent Prostate Cancer (AIPC) [6]. The AIPC
phenotype is closely related to metastasis and decreased survival.
Unfortunately, current treatments for metastatic AIPC have
demonstrated only modest survival advantages [7]. Thus, an
effective therepy for metastatic AIPC represents an unmet medical
need and an ideal target for systems biology.
AIPC is characterized by androgen action in the absence of
androgen stimulation. At the core of androgen action is the
regulation of Androgen Receptor (AR) by hormones such as
testosterone. AR is a cytosolic steroid hormone receptor belonging
to the superfamily of ligand activated transcription factors. Other
members of this family include Vitamin A/D, estrogen, proges-
terone and thyroid hormone receptors [8,9]. In healthy prostate
epithelial cells, androgens activate AR and drive an AR-dependent
gene expression program. Sexual androgens such as testosterone
typically circulate in the blood, bound to proteins such as the Sex
Hormone Binding Globulin (SHBG) protein. Free testosterone
enters prostate cells where the 5a-reductase enzyme converts it to
activated dihydrotestosterone (DHT) [10]. Both cytosolic testos-
terone and DHT can bind AR, however DHT has a higher affinity
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and the translocation of activated AR to the nucleus. Nuclear AR
drives the expression of target genes including PSA by binding to
AR-responsive promoter elements [11,12]. Because of its ligand
dependence, one would expect AR activation and AR-driven gene
expression to be absent without hormone stimulation. However,
AIPC often has higher PSA expression and increased cell-
proliferation compared to its androgen-dependent counterpart
even without stimulation [13,14].
AIPC’s increased proliferation and PSA secretion in the absence
of androgen suggests a failure in the regulation of androgen
receptor activation. Feldman and Feldman reviewed several
possible AR regulatory pathways perhaps responsible for androgen
action in the absence of hormone stimulation [15]. One
hypothesis, referred to as the hypersensitivity pathway, suggests
that AR may be more sensitive to androgen in AIPC. This would
allow AR activation and AR-driven gene expression at much
lower levels of extracellular testosterone signals. Another hypoth-
esis, referred to as the promiscuous pathway, suggests that AR can
be activated by non-androgen antagonists. A third hypothesis,
explored here, suggests that AR can be activated by other
pathways, for example, the Mitogen Activated Protein Kinase
(MAPK) cascade. Several studies support this cross-talk hypothesis,
sometimes referred to as the outlaw pathway. Culig et al. showed in
DU-145 human prostatic tumor cells that growth factors e.g., IGF-
I, KGF, and EGF could drive AR activation without androgen
[16]. Nazareth and Weigel showed in human prostate PC-3 cells
that AR could also be activated by the protein kinase A activator,
forskolin in the absence of androgen [17]. Other studies have
suggested a connection between Her2 induced activation of the
primary MAPK cascade and AR activation [18]. For example,
Her2 overexpression was positively correlated with diminished
sensitivity to androgen ablation, increased AR dependent PSA
expression, increased AR activation, increased tumor mass and
shortened tumor latency [14,18–20]. Thus, one would expect
regulators of Her2 activation, for example the different forms of
the 100 kDa glycoprotein Prostatic Acid Phosphatase (PAcP),
could be important factors in androgen dependence and tumor
grade [21–26]. Intracellular PAcP (cPAcP) whose expression is AR
responsive, downregulates Her2 by dephosphorylation. On the
other had, secreted PAcP (sPAcP) promotes modest Her2
activation by an unknown mechanism [26].
Results
The objective of this study was to determine which signaling
components were important in AI versus AD LNCaP cells.
Toward this objective, we constructed and analyzed a mecha-
nistic mathematical model of the androgen response of three
different LNCaP prostate adenocarcinoma sub-lines. We inves-
tigated MAPK-dependent outlaw activation of AR in AD (C-33),
mid-range (C-51) and AI (C-81) LNCaP cells [13,27]. Our
network model included: nuclear hormone and transmembrane
growth factor receptor activation; transcriptional activity via the
MAPK subsystem [28–30] together with outlaw activation of AR
via MAPK [15,18]; PI3K/AKT/TOR mediated translation
initiation [31,32]; the transcriptional and translational regulation
of PSA, cyclin D and PAcP expression [14,20]; and the regulation
of Her2 activity by PAcP [26] (Fig. 1). The network described 212
species and 384 interactions (Table S1). Transcription and
translation were modeled using elementary reactions based on
literature (supplemental materials). Constitutive and regulated
expression of PSA, cyclin D and the two forms of PAcP were
considered in the model. The total level of all other model
proteins was constant. We modeled the molecular interactions
using mass action kinetic processes within an ordinary differential
equation (ODE) framework. ODEs are a common method of
modeling biological pathways and have been used to model a
range of signal transduction processes [29,33–41]. Mass action
kinetics have also been used extensively, for example, to model
receptor tyrosine kinase signaling [41], blood coagulation [39],
pain networks [40] or Toll like receptor signaling [42,43]. They
have also been a key component in the success of perturbation-
response approaches which have shown that simple linear rules
often govern the response behavior of biological networks [44].
The ODE model was deterministic and captured only population
averaged behavior. While we assumed spatial homogeneity, we
differentiated between cytosolic and membrane localized pro-
cesses. We used mass-action kinetics to describe the rate of each
molecular interaction. Thus, the 384 kinetic model parameters
were mainly association, dissociation or catalytic rate constants.
With one exception, model parameters were estimated and
validated using LNCaP training data taken from literature
sources (Table S2). However, we were unable to estimate unique
model parameters. Instead, we estimated a family or ensemble of
parameters that was consistent with the training data. The
ensemble allowed us to estimate the model uncertainty associated
with the many poorly characterized parameters. We analyzed the
model ensemble to better understand which architectural features
were important in androgen dependent versus independence
cells.
Estimating the Ensemble of Prostate Model Parameters
Signal transduction models often exhibit complex behavior [45–
48]. It is often not possible to identify model parameters, even with
extensive training data [49]. Thus, despite identification standards
[50] and the integration of model identification with experimental
design [51], parameter estimation remains challenging. In this
study, an ensemble of plausible model parameters was estimated
from AI and AD LNCaP sub-clones. Ensemble approaches have
successfully addressed uncertainty in systems biology and other
fields like weather prediction [40,52–55]. Their central value is the
ability to constrain model predictions despite uncertainty. For
example, Sethna and coworkers showed in a model of growth
factor signaling that predictions were possible using ensembles
despite incomplete parameter information (sometimes only order
of magnitude estimates) [46]. They further showed that model
ensembles were predictive using many different mathematical
models [56].
The 420 unknown model parameters (384 kinetic constants and
36 non-zero initial conditions) were estimated using 14 time-series
and steady-state training sets taken from literature sources (Table
S2). The parameter identification procedure used a maximum
likelihood random-walk strategy with a correlation constraint to
identify a diverse family of likely parameter sets (Fig. 2C). We
generated 3210 possible parameter sets and selected 107 of these
for inclusion in the final ensemble. The selection was made to
minimize the correlation between possible sets (materials and
methods). The majority of parameters had a Coefficient of
Variation (CV) of greater than 100%. Thus, although the model
qualitatively recapitulated the training data, many of the
parameters were poorly constrained (Fig. 2B). However, param-
eters involved with key features such as cyclin-D and PSA
expression were relatively well constrained (CVƒ50%). The low
deviation of these parameters could be attributed to the
abundance of PSA/cyclin D training data. Alternatively, it may
suggest that these mechanisms had a large impact on model
behavior. A single network structure described both Androgen
Simulations of Prostate Cancer
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with only two experimentally justified parameter changes. The
parameters controlling the expression rate of cellular PAcP
(cPAcP) and secreted PAcP (sPAcP) were reduced by a factor of
0.01 and 0.5, respectively, for the C-81 and C-51 cell-lines
compared to C-33 (Fig. 2A). The PAcP expression scaling factors
were chosen to correspond with measured steady-state PAcP
expression ratios for the different cell-lines [57]. The kinetic
parameters and non-zero initial conditions for C-33 are given in
Table S1 and Table S3, respectively.
The Ensemble of AI/AD Lncap Models Recapitulated
Androgen Action and the Activity of the Outlaw Pathway
AR can be activated by both hormone dependent and
independent pathways. In this study, we considered both the
traditional hormone dependent and MAPK mediated AR
activation. We selected training data sets to constrain each mode
of AR activation and the subsequent AR-driven gene expression
program. The data of Lee et al., was used to constrain the
relationship between PSA expression and AR activation in AI and
AD cells [14]. Activated AR was modeled as both a transcriptional
Figure 1. Schematic overview of the interaction network used in modeling the androgen response in prostate epithelial cells. The
model architecture was formulated by aggregating molecular modules into a single network (see insert for high level details). The model describes
growth factor and hormone induced expression of cyclin D, PSA and the two forms of PAcP. The complete list of molecular interactions that comprise
the model (along with kinetic parameter values) are given in Table S1.
doi:10.1371/journal.pone.0008864.g001
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PAcP expression [20]. The model recapitulated the qualitative
features of PSA expression at the protein level for C-81 and C-33
(Fig. 3B). Additionally, the basal and increased level of PSA
mRNA following Her2 overexpression in C-33 was also well
described (Fig. 4). The PSA mRNA data was taken from a
separate LNCaP study [18]. The C-33 simulations recapitulated
the observed lower PSA expression (*4 fold) compared to C-81 in
the absence of androgen (Fig. 3B, initial point). Following DHT
stimulation (10nM at t=1 hr) PSA expression increased for both
clones. However, the increase was more significant for C-33
(Fig. 3B). The study of Meng et al. was used to constrain the
relationship between AR activation and PAcP expression [20].
The addition of DHT to C-33 cells decreased PAcP expression
and increased Her2 phosphorylation (Fig. 3A).
The model recapitulated the positive feedback between Her2
induced MAPK activation and androgen action. Several studies
have demonstrated that MAPK can activate AR in the absence of
hormone stimulation. Activated AR transcriptionally down-
regulates cPAcP expression which in turn increases Her2
activation. Both Her2 dimerization along with the traditional
EGFR-growth factor pathway can activate MAPK, leading to a
positive feedback loop. However, typical growth factor induced
MAPK activation is transient whereas de-regulated Her2 induced
MAPK activation is persistent. The MAPK module in the model
described both activation pathways. Growth factor dependent
MAPK activation was constrained by dynamic measurements of
phosphorylated ERK (ERKpp) levels following stimulation of
EGFR with 8nM EGF (Fig. 5D). The EGF induced ERKpp data
was taken from HeLa cells [30]. However, we expect transient
EGF-induced MAPK activation in LNCaP cells will be qualita-
tively similar to HeLa given the conserved nature of mitogenic
signaling. We constrained Her2 induced MAPK activation using
cyclin D protein expression data in C-33 and C-81 cells without
androgen following PAcP expression (Fig. 5C). Cyclin D
expression was coupled to ERK through the ETS and AP1
transcription factors, both of which activate cyclin D expression
[59]. Her2 induced MAPK activation led to a persistent ETSp
signal compared to ETS activation following EGFR-induced
MAPK activation (Fig. 5D, inset). Nominally, C-33 cells have
lower cyclin D expression compared to C-81 (Fig. 5C, lane 1 and
4). The difference in cyclin D expression between C-33 and C-81
cells was qualitatively consistent with increased C-81 proliferation
[13]. While the expression of cPAcP in C-81 reduced cyclin D
levels (Fig. 5C, lane 2), sPAcP expression resulted in no change
(Fig. 5C, lane 3). Furthermore, the model predicted a dose
Figure 2. Identification and properties of the prostate model ensemble. A: Steady state PSA level as a function of cPAcP and sPAcP
expression. The circles represent the values used to model the C-51 and C-81 LNCaP clones. All values are relative to C-33. B: Coefficient of Variation
(CV; standard deviation of a parameter relative to its mean value) for the parameter ensemble used in this study. A small CV suggested a parameter
was tightly constrained by the training data used for model identification. The parameters with the three smallest CVs are listed. C: Parameter
identification strategy. Multiple monte-carlo trajectories were used to randomly explore parameter space. The simulation error and the correlation
between parameter sets was used to generate the family of parameter sets used in the simulation study.
doi:10.1371/journal.pone.0008864.g002
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of DHT (Fig. 6A). Although the cyclin D increase is only notable
in response to high levels of DHT (10 or 100nM) the prediction is
qualitatively consistent with experimental data not included in the
ensemble calculations [60].
To further constrain the relationship between MAPK, Her2
and AR activation, we used the Her2 perturbation study of Lee et
al. [14] in the ensemble calculations. Because the perturbation
magnitudes were not reported, we assumed +50% for all changes.
Where possible, this assumption was validated by analyzing the
corresponding Western blots using the GelEval software package
(v1.22, Frog Dance Software). The +50% perturbation magni-
tude was approximately consistent with the published blots. A 50%
increase in Her2 led to an approximately 50% increase in PSA
expression in C-33 without androgen (Fig. 5A, lanes 1 and 3).
While a 50% decrease in Her2 in C-81 led to a similar decrease in
PSA secretion (Fig. 5B, lanes 1 and 2). Further disruption of Her2
effectively blocked PSA expression in C-81 without androgen
(Fig. 5B, lane 3). A 50% reduction of MEK, one of the three
primary protein kinases in MAPK, resulted in reduced PSA
expression in C-81 (Fig. 5B, lane 4). While a 50% increase of
MEK in C-33 increased PSA expression by 5-fold (Fig. 5A, lane 2).
The combination of MEK inhibition and Her2 activation (50%
increase in Her2 and a 50% decrease in MEK) decreased PSA
expression in C-33 (Fig. 5A, lane 4). Furthermore, the model
predicted an increase in C-33 PSA levels 72 hours after a 2nM
addition of the androgen testosterone. Simulations performed with
10% of the AR initial condition predicted an approximate 50%
decrease in testosterone stimulated PSA (Fig. 6B). The reduced
PSA levels are consistent with reported experimental data on AR
antisense knock-downs in androgen dependent LNCaP cells [61].
This data was not included in the ensemble calculations. Taken
together, the model replicated qualitative features of the
relationship between MAPK, AR activation and androgen action.
In addition, the qualitative agreement between model and
experiments for PSA and cyclin D expression suggested that the
transcription and translation subsystem models were operating
correctly.
Sensitivity and Robustness Analysis Revealed Key
Subsystems in AI and AD Cells
Sensitivity analysis identified interactions important in C-33, C-
51 and C-81 cells (Fig. 7 and Table S4). We calculated overall
State Sensitivity Coefficients (OSSCs) for the three LNCaP clones
over the parameter ensemble (materials and methods). The OSSC
values were ranked-ordered based on their absolute magnitude.
The dissociation of AR from Heat Shock Proteins (HSP),
components of the Akt signaling axis and MAPK activation were
important (top 2% of sensitive interactions) irrespective of
androgen status. Sequestered AR was unable to become activated
by androgens or MAPK. Thus, increased AR-HSP dissociation
promoted increased AR activation and AR-driven gene expres-
sion. Several components of the MAPK cascade were also
important including Ras binding to GAP and Raf, and the
dephosphorylation of ERK. The sensitivity of MAPK was not
unexpected. ERK was critical to outlaw activation of AR.
Moreover, ERK activation was modeled as being Ras dependent.
Figure 3. Simulation results for the addition of 10nm DHT at
1 hour to C-33 and C-81 LNCaP clones. A: Her2 phosphoralation
(circles) and cPAcP expression (squares) for C-33 cells following the
addition of DHT. Experimental data reproduced from Meng et al. [20]. B:
PSA expression following the addition of DHT to C-81 (squares) and C-
33 (circles) LNCaP clones. Experimental data reproduced from Lee et al.
[14]. The shaded region in each plot denotes one standard deviation
centered about the ensemble mean (line).
doi:10.1371/journal.pone.0008864.g003
Figure 4. Simulated PSA mRNA levels in C-33 cells with and
without Her2 overexpression. Her2 overexpression was modeled as
a 50% increase in the expression rate of Her2. Bars denote the mean
PSA mRNA level over the parameter ensemble while error bars denote
one ensemble standard deviation. The experimental PSA mRNA data
was adapted (replotted) from [18].
doi:10.1371/journal.pone.0008864.g004
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steady state PSA levels. The inhibition of MEK blocks the effect HER2 overexpression. Experimental data adapted from Lee et al. [14]. B: Effect of HER2
and MEK inhibition on LNCaP C-33 steady state PSA levels. The inhibition of either HER2 or MEK blocks high AIPC PSA levels. Experimental data
adapted from Lee et al. [14]. C: Effect of PAcP isoforms on LNCaP steady state cyclin D levels. Experimental data adapted from Lingappa and
coworkers (Prosetta Corporation, unpublished data). D: Transient activation of ERK via ligand dependent EGF signaling (8nM EGF at t=60s) in HeLa
cells. The HeLa data was reproduced from [30]. Inset: Simulated phosphorylated ETS (ETSp) levels following the addition of 8nM EGF in the presence
and absence of Her2. Her2 activation drives a sustained MAPK signal which in turns sustained ETS activation. The shaded region denotes one
standard deviation centered about the ensemble mean (line).
doi:10.1371/journal.pone.0008864.g005
Figure 6. Independent model predictions versus experimental observations. A Ensemble prediction of cyclin D expression following the
addition of DHT at 1 hour to C-33 clones. The ensemble predicted a dose dependent increase of cyclin D at 24 hours after DHT addition.
Experimental data was adapted from Barnes-Ellerbe et al. [60]. B Predicted effect of an AR knockdown on PSA expression following the addition of
androgen at 1 hour to C-33 wild-type and C-33 AR knock-down clones. The ensemble predicted an approximate 50% decrease in androgen
stimulated PSA expression due to AR knock-down 72 hours after treatment. Experimental data was reported by Eder et al. [61]. The error bar denotes
one standard deviation centered about the ensemble mean.
doi:10.1371/journal.pone.0008864.g006
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top 2% of sensitive interactions irrespective of androgen status. For
example, the formation of PIP3, an early step in the PI3K/Akt
signaling axis regulated by PTEN, was found to be highly sensitive
in all clones. Looking beyond the upper 2% of sensitive
interactions, additional common mechanisms were identified.
These included AR interactions with DHT, recruitment of adapter
molecules by Her2, activation of ERK by MEKpp and additional
regulation of PIP3 formation by PTEN.
Translation interactions became more fragile while transcrip-
tion became more robust with increasing androgen indepen-
dence. Her2 auto-activation and Her2 cPAcP interactions were
also increasingly important with increasing androgen indepen-
dence. The difference in the importance of interactions in AI
versus AD LNCaP clones was estimated by computing shifts in
the sensitivity rankings (Table S5). In addition to considering C-
33 and C-81, we analyzed a third clone, C-51, which was
moderately androgen dependent. There were 117 statistically
significant shifts (52 more and 65 less sensitive) between the C-81
and C-33 clones. However, only 14 shifts were larger than one
standard above the mean shift. Of the 14 large shifts, 50%
involved PSA and PAcP translation while the remainder were
associated with Her2 and cPAcP. Conversely, PSA transcription
became more robust with increasing androgen independence.
Similarly, when comparing C-33 to C-51, PSA translation and
Her2 activity became more sensitive with increasing androgen
independence. Inspection of the importance of the final step in
PSA transcription and translation among the individual models in
the ensemble showed a shift away from transcription (Fig. 7C)
toward translation (Fig. 7D) across the population of models. The
increasing importance of translation was not limited to PSA,
although PSA was the most significant example. Globally, 16 of
the 52 interactions that were more sensitive in C-81 involved
translation while only 4 of 52 involved transcription. No
translation mechanisms became more robust in C-81 compared
to C-33. Similar to PSA, translation of other key proteins such as
cPAcP became more sensitive in C-81 versus C-33. Of the
statistically significant shifts, 7/9 of the cPAcP translation
interactions were more sensitive in C-81. Additionally, both
mechanisms for the phosphorylation of 4E-BP1 by TOR kinase, a
key step in translation initiation that liberates eIF4E, were also
more importance in C-81. Taken together, the sensitivity analysis
suggested that the fragility of the translational subsystem directly
correlated to androgen independence.
Figure 7. Sensitivity analysis of the model parameters. A: Comparison of the mean OSSC parameter ranks for the C-33 and C-81 LNCaP
models. Large ranks indicate fragility. Points left of the 45o line are more important in C-33, while shifts to the right show increased importance in C-
81. Points are organized by biological function. B: Comparison of the mean OSSC parameter ranks for translation mechanisms (including the role of
Akt signaling in translation initiation) in C-33 versus C-81 LNCaP clones. The error bars indicate one standard deviation centered about the mean
ensemble value. C: The final mechanism in PSA transcription becomes increasingly more robust w.r.t cancer aggressiveness, as indicated by a
significant reduction in mean OSSC Rank. D: The final mechanism in PSA translation (translation termination) was increasingly fragile w.r.t cancer
aggressiveness, as indicated by a significant increase in mean OSSC rank. The results indicate a shift in the bottle neck for generation of PSA from
transcription to translation as prostate cancer cells lose their androgen dependence. The top and bottom of each box denote the 25th and 75th
percentile of the OSSC rank over the parameter ensemble. The center line denotes the median value. Whiskers show the furthest observations and
black crosses indicate outliers.
doi:10.1371/journal.pone.0008864.g007
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clones we preformed robustness analysis on four functional
protein markers. The initial conditions of seven key protein
species were altered by a factor of 10, .1 or 0 for knock-in,
knock-down or knock-out perturbations, respectively. We then
calculated the effect of these perturbation on cyclin D and PSA
expression levels along with ERK and AR activation levels.
Perturbation of Raf, MEK or ERK had similar effects on the
functional markers with ERK being the most notable (Fig. 8,
lanes 1, 2 and 3). Trivially, ERK perturbations directly effected
ERK activation levels. However, more importantly, ERK
perturbations greatly effected cyclin D expression levels. ERK
knock-ins approximately doubled cyclin D while ERK knock-
outs reduced cyclin D to less then one third of wild-type levels.
The functional markers were robust to perturbations in AKT
and TOR with differing effects on ERK activity and slight
decreases in expression levels upon AKT or TOR knock-out
( F i g .8 ,l a n e s4a n d5 ) .F u r t h e r m o r e ,t h et r a n s l a t i o ni n i t i a t i o n
factor eIF4E demonstrated a limiting reagent behavior in the
expression of both cyclin D and PSA while perturbations in 4E-
BP1 had little effect (Fig 8, lanes 6 and 7). However, the 4E-
BP1 results could be an artifact of artificially high background
levels of eIF4E as no direct eIF4E measurements were included
in the training data. Knock-in simulations of eIF4E demon-
strated an 8.7 and 5.2 fold increase in cyclin D and PSA
expression. Reduction of eIF4E resulted in a 89% loss of
expression and, full knock-out simulations predicted a complete
loss of cyclin D and PSA.
The MAPK and Akt Pathways Synergistically Activated
Cyclin D Expression
Complex systems composed of interacting subsystems can
display emergent properties that are not explained by the
individual subsystems alone [62]. In cancer biology, it is
common to speak of signal transduction pathways as if they
w e r ei s o l a t e d .I nr e a l i t y ,t h e s ecomponents are highly intercon-
nected and can interact in a variety of ways sometimes leading
to unpredictable behavior. In this study, we explored whether
the MAPK and Akt signaling axes synergistically activated the
expression of cyclin D. We compared the steady-state cyclin D
expression in Akt and ERK knock-outs with wild-type C-81 cells
in the absence of androgens. At steady-state, the MAPK and Akt
pathways synergistically (DcycDw0) activated cyclin D expres-
sion in C-81 cells without androgen (Fig. 9A). Thus, steady-state
cyclin D expression was greater in wild-type cells (Aktz-ERKz)
than the linear combination of cyclin D expression in Akt{-
EKTz and Aktz-ERK{ cells. The above-additive (superlinear)
cyclin D expression was statistically significant within a 95%
confidence interval. However, the relatively large standard
deviation suggested that cyclin D expression varied widely
across the ensemble. To address this, we inspected every model
i nt h ee n s e m b l ea n df o u n dt h a t each predicted an above-
additive increase in cyclin D expression (data not shown).
Superlinear cyclin D expression may be the result of positive
synergy between the MAPK and translation subsystems. To
elucidate the underlying mechanisms responsible for synergy we
expanded the analysis to include all modeled species (both
proteins and protein complexes) and rates. Many functional
network subunits demonstrated no statistically significant
deviations from additive behavior (Fig. 9C, grey). However,
22 species (79 interactions) were negatively coupled to Akt/
ERK (Djv0; Fig. 9B, red) while 14 species (37 interactions) had
a positive synergy (Djw0;F i g .9 B ,g r e e n ) .S y n e r g yb e t w e e nt h e
MAPK and Akt signaling subsystems negatively effected
transcription factor activation. Phosphorylated ERK (ERKpp)
activated AR (pAR), and the transcription factors AP1 and ETS
all showed a below additive response (Fig. 9B). Conversely,
positive synergy was almost exclusively limited to translation
interactions. The binding of eIF4E, 40S and 60S ribosomes to
form the mRNA initiation complex, elongation and termination
steps all had positive synergy with ERK/Akt knockdowns
(Fig. 9B).
Figure 8. Robustness analysis of functional protein markers. The expression level of seven key proteins was altered by a factor of 10, .1 or 0
(knock-in, knock-down or knock-out) and robustness coefficients (area under the curve for the perturbed versus wild-type simulation) were calculated
for cyclin D and PSA expression levels along with ERK and AR activation levels. Simulations were run for C-81, with the indicated perturbation, to
approximate steady-state and 10nM of DHT was added for 72 hours. Ensemble mean values are reported.
doi:10.1371/journal.pone.0008864.g008
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A critical milestone in prostate cancer progression is the onset of
androgen independence. In this study, we formulated and
analyzed an ensemble of mathematical models of the androgen
response of AI and AD LNCaP prostate cancer epithelial cells.
The model ensemble was identified using 14 different steady-state
and dynamic data sets taken from literature. With the exception of
one study, all the training data was generated in LNCaP cell-lines.
We estimated which molecular subsystems were important in AI
versus AD cells using sensitivity analysis. For example, the
assembly and regulation of Her2 adapter complexes and the
regulation of ERK were sensitive irrespective of androgen status.
The dissociation of AR from HSP was also in the top 2% of
sensitive interactions for both C-33 and C-81. On the surface, the
importance of AR in C-81 was surprising as the proliferation of C-
Figure 9. Synergy analysis between the ERK and Akt signaling axes in LNCaP C-81 cells. The double ERK and Akt knock-out was
used as the control. A: The difference in steady state cyclin D expression (compared to the control) with the knock-in of Akt (left), ERK (center) and
both (right). The predicted cyclin D levels were normalized by the basil C-81 steady state cyclin D level in each case. The error bars denote one
standard deviation centered about the ensemble mean. The region denoted by the asterisks represents above-additive cyclin D expression. B:
Species and interactions that demonstrated a positive (negative) synergy are shown as green (red) in the connectivity diagram. Species or
interactions not effected are shown in grey. C: The full connectivity diagram qualitatively clustered in functional groups. Positive (negative) synergy
are shown in green (red) in the connectivity diagram. Species or interactions not effected are shown in grey.
doi:10.1371/journal.pone.0008864.g009
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independently of androgen, thus, the presence of androgen is not
required for androgen action [15,63]. The differentiating factor
between the AI and AD models described here was the expression
rate of PAcP conformers. We demonstrated the ability of
decreased PAcP expression to describe the PSA levels of
increasingly androgen independent sub-lines. Moreover, interac-
tions involving Her2 auto-phopshporylation, cPAcP availability
and cPAcP phosphatase activity were significantly more fragile in
C-81 versus C-33. These results suggest that the regulation of the
phosphorylation state of Her2 by cPAcP may be a critical
interaction controlling androgen action in the absence of hormone
signals. Experimentally this has been demonstrated as forced
expression of PAcP is sufficient to suppress C-81 xenograft tumor
growth [64].
Model analysis suggested that translation interactions were more
fragile and transcription more robust in AI versus AD cells.
Globally, 16 of the 52 interactions that were more sensitive in C-81
involved translation while only 4 of 52 involved transcription.
Moreover, no translation mechanisms became more robust in AI
versus AD cells. The importance of translation in more aggressive
cancers (increasing androgen independence) may be due, in-part, to
synergies between the Akt and MAPK pathways. Simulations of
ERK and/or Akt knockouts showed an above-additive response
almost exclusively limited to translation upon the simultaneous
reinstitution of Akt and ERK. In-vivo studies of AIPC have
demonstrated positive synergies between the MAPK and Akt
pathways. Gao et al. observed above-additive tumor growth rates in
castrated and mock nude male mice upon the forced expression of
constitutively active Akt and B-RafV600E [65]. These experiments
suggest that cell proliferation may be regulated by a complex
integration of the MAPK and Akt signaling axes. Our robustness
analysis suggested that independent perturbations in TOR and
AKT may have little or no effect on AIPC. However, we observed
the possibility of an inverse relationship between TOR and ERK
activation. This suggests that if TOR or Akt were to be
independently targeted, AKT might be a more suitable therapeutic
target. Additionally, we observed that perturbations in Raf, MEK
and ERK had a similar effect on cyclin D but not PSA expression,
with ERK being more pronounced. Current therapeutics such as
trastuzumab or gefitinib, which target either Her2 or EGFR
respectively, have had little efficacy against hormone-refractory
prostate cancers [66,67]. Our results suggest that a possible factor in
their lack of effectiveness is that they fail to address synergy between
growth factor signaling, MAPK activation and the Akt signaling
axes. Our analysis also demonstrated that translation mechanisms
were generally more sensitive in increasingly androgen independent
models. The translation results suggest that the direct targeting of
the translation machinery may be useful for the treatment of AIPC.
Our robustness analysis identified eIF4E as a limiting reagent in the
expression of both cyclin D and PSA in C-81 clones. Soni et al.
demonstrated the effectiveness of directly targeting eIF4E in breast
cancer. Down-regulation of eIF4E resulted in decreased cyclin D
expression and decreased growth rate without the deleterious effect
of inhibitors such as rapamycin which act further upstream [68].
Previous modeling studies from our laboratory have also demon-
strated the importance of translation beyond cyclin D [69].
However, the current model has only a basic description of
translation initiation. Moreover, translation parameters were only
indirectly trained from the PSA mRNA and protein data. Thus,
while the initial robustness and sensitivity results are encouraging
more studies are needed.
Analysis of the ensemble of AI models suggested the Akt and
MAPK pathways synergistically enhanced cyclin D expression by
up-regulating translation. Cyclin D is expressed early in the cell
cycle and a point of convergence in the proliferative action of
multiple receptors [70]. Many studies have identified a direct
correlation between cyclin D regulation and prostate cancer, as
well as breast and non-small cell lung cancer [71–73]. Balk et al.
demonstrated that increased cyclin D expression in PTEN{={
LNCaP cells following DHT addition was largely because of
increased translation [74]. PTEN loss and presumably the
activation of Akt has been implicated with increased translation
and the resistance to therapeutics which target Her2 and EGFR
[75,76]. However, the underlying mechanism responsible for the
increased translation in the Balk et al. study was not solely AKT
dependent. Early translation activation was due to PI3K/Akt
signaling but TOR activation at later time points was Akt
independent. One key difference between the modeling and the
Balk et al. study was the binding of activated AR with the
regulatory subunit of PI3K. This interaction, which was not
included in the model, was at least partially responsible for TOR
activation and the eventual liberation of eIF4E. In addition to
direct AR binding, PI3K (and subsequently TOR) can be
activated through receptor adaptor complexes such as those
associated with Her2. In the model, PI3K was activated by
androgen (in the absence of growth factor) because of the down-
regulation of cPAcP expression by activated AR. Upregulated
PI3K then drove Akt dependent activation of TOR which led to
enhanced liberation of eIF4E from 4E-BP1. Thus, while the
initiating events driving TOR activation were different, the
subsequent up-regulation of cyclin D translation was similar. This
suggests that the model prediction of a complex synergy between
interacting signaling axes may be valid. It also suggests a falsifiable
hypothesis that cPAcP could be critical to enhanced translation
following androgen stimulation.
The role of mechanistic mathematical modeling in drug design
remains unclear. A common criticism of such techniques has been
the poorly characterized effect of model uncertainty. Model
uncertainty has two forms. Structural uncertainty is defined as
uncertainty in the biology, while parametric uncertainty is defined
as incomplete knowledge of parameter values. In this study,
parametric uncertainty was minimized by considering a family of
consistent models instead of a single best-fit but uncertain model.
While model ensembles often poorly constrain individual param-
eter values, they may robustly constrain model predictions [56].
Structural uncertainty was addressed by considering only
molecular interactions supported by experimental evidence.
However, the current model contained some abstracted pathways
and should be expanded to include additional biology. For
example, the analysis highlighted the importance of translation.
However, the current model contains a limited description of
initiation factor activation and the assembly of the 80S initiation
complex. A more detailed translation interaction network could
further refine which translation components were important in AI
versus AD cells. Another example is the mechanism by which AR
transcriptionally regulates the expression of target genes. In the
current model we ignored the role of transcriptional co-regulators
and assumed activated AR functioned alone. While this is a
reasonable first approximation, well known co-repressors and
activators [77] such as ARA70 [78] should be included. The
regulation and activity of these co-regulators may be different in
AI versus AD cells and could enhance the list of differentially
important targets. Additionally, a nuclear compartment and
enhanced cell cycle and cell death subnetworks should be added
to the model. These additional networks could be critical to
understanding cell proliferation and survival effects in AI versus
AD cells. For example, androgen and AR are known to regulate
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cells, not just cyclin D [79]. Moreover, the model describes the
activation of Akt in the context of translation initiation, but not its
well know survival functions [80,81]. Lastly, given the importance
of EGFR and Her2 induced MAPK activation in the current study
and the therapeutic emphasis on receptor inhibition we plan to
include a more complete receptor signaling network. Other
receptors, IGFR and IL-6R have also been implicated in prostate
cancer [82–84]. Understanding the signaling associated with these
receptors and their downstream targets should be considered and
will provide a better representation of how intra- extra-cellular
communication drives cell fate decisions. Furthermore, the
application of advanced sampling techniques may allow for a
more exhaustive investigation of parameter space. For example,
multi-objective optimization ensemble techniques could be used to
balance conflicts in the training data [40]. Additionally, under-
standing the topological details of the cost function in an extended
parameter space could provide statistical information on kinetic
rates and initial conditions. Other techniques, for example the
calculation of the mutual information matrix, could also provide
insight into correlations between model interactions. Also,
computation of second order sensitivity coefficients would allow
the identification of possible synergies in the model. Thus, we
expect that deeper insight could be generated by extending the
network structure and through the application of advanced model
analysis tools.
Materials and Methods
Formulation and Solution of the Model Equations
The prostate model was formulated as a set of coupled Ordinary
Differential Equations (ODEs):
dx
dt
~S:rx ,k ðÞ x to ðÞ ~xo ð1Þ
The symbol S denotes the stoichiometric matrix (212|384). The
quantity x denotes the species concentration (212|1). The term
rx ,p ðÞ denotes the vector of reaction rates (384|1). Each row in S
described a species while each column described the stoichiometry
of network interactions. Thus, the (i,j) element of S, denoted by
sij, described how protein i was involved in rate j.I fsijv0, then
protein i was consumed in rj. Conversely, if sijw0, protein i was
produced by rj. Lastly, if sij~0, protein i was not involved in rate
j.
We assumed mass-action kinetics for each interaction in the
network. The rate expression for protein-protein interaction or
catalytic reaction q:
X
j[ Rq fg
sjqxj?
X
p[ Pq fg
spqxp ð2Þ
was given by:
rq x,kq
  
~kqP
j[ Rq fg
x
{sjq
j ð3Þ
The set Rq
  
denotes reactants for reaction q. The quantity
Pq
  
denotes the set of products for reaction q.T h ekq term
denotes the rate constant governing the qth interaction. Lastly,
sjq,spq denote stoichiometric coefficients (elements of the matrix
S). We treated every interaction in the model as non-negative. All
reversible interactions were split into two irreversible steps. The
mass-action formulation, while expanding the dimension of the
prostate model, regularized the mathematical structure. The
regular structure allowed automatic generation of the model
equations. In addition, an analytical Jacobian (A)a n dm a t r i xo f
partial derivatives of the mass balances with respect to the model
parameters (B) were also generated. Mass-action kinetics also
regularized the model parameters. Unknown model parameters
were one of only three types, association, dissociation or catalytic
rate constants. Thus, although mass-action kinetics increased the
number of parameters and species, they reduced the complexity
of model analysis. In this study, we did not consider intracellular
concentration gradients. However, we accounted for membrane
and cytosolic proteins by explicitly incorporating separate
membrane and cytosolic protein species. We did not consider a
separate nuclear compartment.
Simulation Protocol
An approximate steady-state was used as the starting point (t~0
hr) for all simulations presented in this study. For example, when
calculating the response of LNCaP to the addition of DHT, we
first ran the model to steady-state and then simulated the addition
of DHT. Although no individual cell is likely to be at steady-state
we assumed that steady-state was a reasonable approximation of
the population average behavior of LNCaP cells growing in the
exponential phase. The steady-state was estimated numerically by
repeatedly solving the model equations and estimating the
difference between two subsequent time points:
Ex tzDt ðÞ {x t ðÞ E2ƒe ð4Þ
The quantities x t ðÞand x tzDt ðÞ denote the simulated concen-
tration vector at time t and tzDt, respectively. The quantity E:E2
denotes the L2 vector norm. In this study, we used Dt~50 hrs of
simulated time and e=0.01 for all simulations.
Estimation of the Prostate Model Parameter Ensemble
An initial set of model parameters, denoted by p0, was chosen
by hand to replicate the training data. The training data consisted
of 14 time-series and steady-state data sets taken from literature
sources (Table S2). The initial parameter guess p0 was used to
generate an ensemble of parameters that maximized the likelihood
of describing the training data. The difference between the
measured and simulated value of species j at time or condition i,
denoted by ^ x xi,j and x(pk)i,j respectively, was quantified by the
normalized mean squared error, g:
g pk ðÞ ~
1
N
X
i,j
(^ x xi,j{bjx pk ðÞ i,j)
2
^ s s2
i,j
, ð5Þ
where the sum was carried out over all species j and observations i.
The quantities N and ^ s si,j denote the total number of observations
and the measurement standard deviation of species j at time or
condition i, respectively. If no experimental error was reported, we
assumed a standard deviation equal to 10% of the reported
observation. In cases where the quantification of the stimulus or
observation was unclear an augmented error of 20%–100% was
applied to compensate for the added uncertainty. bj is a scaling
factor which is required when considering experimental data that
is accurate only to a multiplicative constant (assumed here to be
the case form immunobloting analysis). The scaling factor was
chosen to minimize the normalized squared error between a given
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bj~
P
i
(^ x xi,jxi,j=^ s s2
i,j)
P
i
(xi,j=^ s si,j)
2 : ð6Þ
Because of the scaling factor, the concentration units on simulation
results were arbitrary (consistent with the arbitrary units on the
majority of the training data). All simulation outputs reported in
this study were scaled by the corresponding bj. There was
insufficient training data to properly constrain the 420 model
parameters. To account for parametric uncertainty, a monte-carlo
approach similar to Battogtokh et al. [52] was used to generate an
ensemble of parameters. Consider a set of model parameters pi.
Let the likelihood that model simulations with parameters pi
describe the training data be defined as:
w(pi):expf
{g(pi)
a
g, ð7Þ
where g(pi) denotes the simulation error associated with parameter
set pi. The quantity a is a parameter used to tune the rate of
acceptance. Further let the acceptance probability, P(p
0
iz1jpi),o f
a new parameter set, p
0
iz1,b e
w(p
0
iz1)
w(pi)
if w(p
0
iz1)vw(pi) and 1
otherwise. P denotes the probability that p
0
iz1 will be accepted as
pi for consecutive monte-carlo steps. Parameter sets were generated
by applying a small additive random perturbation in log space:
logp
0
iz1~logpizN 0,n ðÞ ð 8Þ
where N 0,n ðÞ is a normally distributed random number with zero
mean and variance n. The perturbation was applied in log space to
account for the large variation in parameter scales and to ensure
positivity. Monte-carlo trajectories were generated starting from p0
where n~0.05 or 0.1and a~1 or 0.5. The autocorrelationfunction
of each trajectory was calculated. The number of monte-carlo steps
between parameter sets which were added to the ensemble was
taken to be the number of steps after which the autocorrelation
function dropped to 5% of its initial value. This was done to ensure
independence between sets in the ensemble. To compensate for
noise in the autocorrelation function an exponential fit was applied.
The final ensemble contained 107 parameter sets, which produced
an ensemble g of 5.25.
Sensitivity Analysis of the Prostate Network
Overall State Sensitivity Coefficients (OSSC) were used to
estimate which structural elements of the prostate network were
sensitive [35]. OSSC values were determined by first calculating
the first-order sensitivity coefficients at time tk:
sij tk ðÞ ~
Lxi
Lpj
       
tk
ð9Þ
First-order sensitivity coefficients were computed by solving the
matrix differential equation:
dsj
dt
~A t ðÞ sjzbj t ðÞ j~1,2,...,P ð10Þ
subject to the initial condition sj(t0)~0. In Eqn. 10, j denotes the
parameter index, P denotes the number of parameters in the
model, A denotes the Jacobian matrix, and bj denotes the jth
column of the matrix of first-derivatives of the mass balances with
respect to the parameter values (denoted by B). An analytical
Jacobian and matrix of first-derivatives of the mass balances w.r.t
the parameters:
A~
Lfx
Lx
       
(x ,p )
B~
Lfx
Lp
       
(x ,p )
ð11Þ
were generated from the model equations. The quantity
fx~S:rx ,p ðÞ and x ,p  ðÞ denotes a point along the unperturbed
model solution. The sensitivity equations required that we solve
the model equations to evaluate the A and B matrices. Thus, we
formulated the sensitivity problem as an extended kinetic-
sensitivity system of equations [85]:
_ x x
_ s sj
  
~
S:rx ,p ðÞ
A t ðÞ sjzbj t ðÞ
  
j~1,2,...,P ð12Þ
where _ x x~dx=dt and _ s sj~dsj=dt. We solved the kinetic-sensitivity
system for multiple parameters in a single calculation using the
LSODE routine of OCTAVE (www.octave.org). The first-order
sensitivity coefficients were then used to calculate the OSSC value
for parameter j:
Oj t ðÞ ~
pj
Ns
X NT
k~1
X Ns
i~1
1
xi
Lxi
Lpj
       
tk
"# 2 0
@
1
A
1=2
ð13Þ
The terms NT,Ns denote the number of time points considered
and the state dimension of the model, respectively. To account for
parametric uncertainty, OSSC values were calculated over the
parameterensemble. Parameterswereranked-ordered (1ƒhjƒ384)
based upon the magnitude of the OSSC value. Large values of hj
indicated fragile or important interactions in the prostate network
architecture. Conversely, small values of hj indicated robustness.
Each model in the ensemble was run to approximately steady
state. At steady-state, 10nM DHT was added and the first order
sensitivity coefficients were calculated for 100 seconds of simulated
time. OSSC values were then calculated and the rank ordering
determined. We collected interactions whose rank was at least one
standard deviation above the mean rank calculated over all
parameters. Highly ranked interactions were statistically signifi-
cantly different between LNCaP clones if the null hypothesis could
be rejected with 95% confidence via a t-test. To estimate
significance, we performed a two variable unequal variance
double tail t-test using the MATLAB (R) statistical toolbox (2007a,
The Mathworks, Natick, MA).
Robustness Analysis of Functional Protein Markers
Robustness coefficients of the form:
a i,j,to,tf
  
~
ðtf
to
xi t ðÞ dt
   {1 ðtf
to
x
(j)
i t ðÞ dt
  
ð14Þ
were calculated to understand the regulatory connectedness of
functional protein markers in the LNCaP network. The robustness
coefficient a i,j,to,tf
  
is the ratio of the integrated concentration of
a network output in the presence (numerator) and absence
(denominator) of structural or operational perturbation. Here t0
and tf denote the initial and final simulation time respectively.
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t0, 10nM of DHT was added at 1 hour and tf was taken to be
72 hours after DHT addition. The network output was taken to be
the network states. The quantity i denotes the index for a marker
or reference species while j denotes the perturbation index,
respectively. If a i,j,to,tf
  
w1, then the perturbation increases the
output concentration. Conversely, if a i,j,to,tf
  
%1 the perturba-
tion decreases the output concentration. Lastly, if a i,j,to,tf
  
*1 the
perturbation does not influence the output concentration.
Calculation of Steady-State Synergy Coefficients
To understand the connectedness of subsystems in the prostate
network following ERK and/or Akt knockdowns we computed
synergy coefficients of the form:
Dj~
dxj,ErkzAkt{(dxj,Erkzdxj,Akt)
xj,total
ð15Þ
The quantity xj,total denotes the steady-state concentration (flux) of
species (interaction) j in wild-type C-81. The quantity dxj,Erk
(dxj,Akt) denotes the steady-state concentration (flux) of species
(interaction) j in the presence of an Akt (ERK) knock-out minus
the basal value of quantity j. The term dxj,ErkzAkt denotes the
steady-state concentration (flux) of species (interaction) j in wild-
type C-81. If Djw0, the quantity j has a positive synergy with Akt
and ERK. In other words, the steady-state concentration (flux) of
species (interaction) j in the wild-type was greater than the sum of
the individual contributions in single Akt or ERK knock-down-
outs. Conversely, if Djv0, the quantity j has a negative synergy
with Akt and ERK. Lastly, if Dj*0 then there is no connection
between quantity j and the Akt/ERK signaling axes.
Supporting Information
Table S1 Prostate model interactions and parameters for the C-
33, C-51, and C-81 LNCaP clones. The kinetics of binding and
catalytic interactions were assumed to follow mass-action rate laws.
The quantity kon denotes forward rate constants, koff denotes
backward rate constants, and kcat denotes catalytic rate constants.
Allbindinginteractionswereassumed to be reversible.Thecitations
listed were the primary source of information for the corresponding
interaction, and include either the exact interaction (i.e., from
preexisting model) or evidence from which the interaction was
inferred. Unless otherwise specified, concentration units were
arbitrary (A.U) as a result of arbitrary units on training data. Thus,
zero-order rate constants had units of A:Us¡1, first-order rate
constants had units of s¡1, and second-order rate constants had units
of (A:U)¡1s¡1 The mean and standard deviation over the parameter
ensemble are reported for each kinetic parameter. |
|: The expression
of the PAcP isoforms, PSA, and cyclin D was implemented using
the same translation/transcription heuristic, save any specific
transcription factors. ?: Her2 adaptor complex reactions were taken
to be similar those of EGFR (66). y: Inferred from collaboration
with Prosetta Cooperation (http://www.prosetta.com/). z: Inter-
nalized EGFR complexes were assumed to signal identically to
membrane-bound EGFR (30,67).
Found at: doi:10.1371/journal.pone.0008864.s001 (0.07 MB
XLS)
Table S2 Experimental training data used to estimate the
ensemble of prostate model parameters.
Found at: doi:10.1371/journal.pone.0008864.s002 (0.02 MB
PDF)
Table S3 Non-zero initial conditions estimated from the training
data for the C-33 LNCaP clone. The mean (m) and standard
deviation (s) calculated over the ensemble are shown.
Found at: doi:10.1371/journal.pone.0008864.s003 (0.03 MB
PDF)
Table S4 Interactions determined to be significantly fragile for
the C-33, C-51, and C-81 LNCaP clones. Overall state sensitivity
coefficients (OSSCs) were calculated over the parameter ensemble.
The OSSC values were ranked ordered. The mean rank and
standard deviation for interactions with rank greater than at least
one standard deviation above the overall mean rank are reported.
Found at: doi:10.1371/journal.pone.0008864.s004 (0.03 MB
PDF)
Table S5 Statistically significant sensitivity differences between
AI and AD LNCaP clones. Negative changes in the mean rank
denote interactions that were more sensitive in AI versus AD cells.
Found at: doi:10.1371/journal.pone.0008864.s005 (0.02 MB
PDF)
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